The Febrile Neutropenia market is expected to experience continued expansion during the forecast period, driven by rising cancer incidence and chemotherapy treatment volumes, increasing awareness of neutropenia risks, and the development of outpatient cancer care. The entry and expansion of low-cost biosimilars alongside new emerging therapies is anticipated to significantly transform the Febrile Neutropenia market landscape and treatment dynamics.
DelveInsight’s “Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Febrile Neutropenia, historical and forecasted epidemiology as well as the Febrile Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan.
The Febrile Neutropenia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Febrile Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Febrile Neutropenia Market Forecast
Some of the key facts of the Febrile Neutropenia Market Report:
- The Febrile Neutropenia market size was valued at USD 4,750 Million in 2025 and is anticipated to reach USD 6,700 Million by 2036, growing at a CAGR of 3.2% during the study period (2026-2036).
- In June 2025, Evive Biotech signed an exclusive distribution agreement with Lenis farmacevtika to commercialize efbemalenograstim alfa across eight markets, including Slovenia, Croatia, Serbia, and others in the Adriatic region. The partnership aims to expand regional access to innovative oncology supportive care, leveraging Lenis’ strong distribution network across Central and Eastern Europe.
- In April 2025, Evive Biotech and I’ROM GROUP announced the start of collaboration to develop efbemalenograstim in Japan. The partnership will focus on advancing a same-day dosing regimen with chemotherapy supported by global clinical data and investigator-led studies showing comparable safety and efficacy to next-day dosing.
- In November 2022, Evive Biotech announced that it has entered into a license agreement with Acrotech Biopharma, a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc., to commercialize RYZNEUTA in the US.
- The total chemotherapy usage per year in the 7MM was 1,906,000 in 2025, of which the United States accounted for the largest share at approximately 36%.
- In 2025, chemotherapy-associated cases accounted for 692,000 in the US and this number is projected to increase to 841,500 by 2036, growing at a CAGR of 1.8%.
- Among the EU4 and the UK, Germany recorded the highest number of incident cases in 2025, accounting for approximately 24% of the total incident cases across these regions.
- Key Febrile Neutropenia Companies:Evive Biotech , Acrotech Biopharma Inc , APOGEPHA Arzneimittel GmbH , Teva Pharmaceuticals , Assertio , Kyowa Kirin, Inc.- U.S. , Terumo Medical Corporation , BeyondSpring and others.
- Key Febrile Neutropenia Therapies: RYZNEUTA [F-627 (efbemalenograstim alfa)], Lipegfilgrastim (LONQUEX), Filgrastim (GRANIX), Eflapegrastim-xnst (ROLVEDON), Pegfilgrastim (G-LASTA), Plinabulin, and others
- The febrile neutropenia epidemiology based on gender analyzed that the incidence shows a higher trend among males compared to females, suggesting a relatively greater susceptibility in male patients.
- Febrile neutropenia shows a higher incidence rate in hematological malignancies than in solid tumors; however, the overall number of cases is greater in solid tumors due to their higher patient population.
Febrile Neutropenia Overview
Febrile Neutropenia is a high-risk clinical condition characterized by the development of fever during a period of significant neutropenia, typically following cytotoxic chemotherapy. It represents a profound disruption of innate immunity, making even minor infections potentially life-threatening. The condition is managed as a medical emergency with immediate empiric broad-spectrum antibiotics, and supportive measures such as Granulocyte-Colony Stimulating Factor (G-CSF) agents may be used in selected cases based on patient risk status.
Get a Free sample for the Febrile Neutropenia Market Report: https://www.delveinsight.com/sample-request/febrile-neutropenia-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Febrile Neutropenia Market
The dynamics of the Febrile Neutropenia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and increasing biosimilar penetration during the forecast period 2022-2036. The market has transitioned from a high-cost, monopolistic landscape dominated by originator biologics to a more competitive, volume-driven market with biosimilars now playing a central role in driving growth and access.
Febrile Neutropenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Download the report to understand which factors are driving Febrile Neutropenia epidemiology trends @ Febrile Neutropenia Epidemiological Insights
Febrile Neutropenia Epidemiology Segmentation:
The Febrile Neutropenia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
- Patient Burden Assessment
- Chemotherapy Usage
- At Risk Patient Pool for Febrile Neutropenia
- Total Incident Cases of Febrile Neutropenia
- Febrile Neutropenia Incident Cases by Cancer Types (Solid vs. Hematologic Malignancies)
- Gender-specific Incident Cases of Febrile Neutropenia
- Comorbidity-Specific Rate of Febrile Neutropenia
- Prophylaxis/Treatment Eligible Patient Pool
Febrile Neutropenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Febrile Neutropenia market or expected to get launched during the study period. The analysis covers Febrile Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Febrile Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Febrile Neutropenia Therapies and Key Companies
- RYZNEUTA [F-627 (efbemalenograstim alfa)]: Evive Biotech/Acrotech Biopharma/APOGEPHA Arzneimittel GmbH
- Lipegfilgrastim (LONQUEX): Teva Pharmaceutical
- Filgrastim (GRANIX): Teva Pharmaceutical
- Eflapegrastim-xnst (ROLVEDON): Assertio Holdings (Spectrum Pharmaceuticals)
- Pegfilgrastim (G-LASTA): Kyowa Kirin/Terumo Corporation
- Plinabulin: BeyondSpring Pharmaceuticals
To know more about Febrile Neutropenia treatment, visit @ Febrile Neutropenia Medications
Febrile Neutropenia Market Drivers
- Rising cancer incidence across global markets, primarily driven by aging populations, improved screening programs, and enhanced diagnostic capabilities
- Increasing reliance on chemotherapy as a standard treatment approach, elevating the risk of treatment-related complications
- Growing demand for novel therapies in community oncology clinics with competitive clinical profiles
- Expanding demand for treatments that are easy to administer, reduce hospital visits, and improve patient outcomes
- Entry and expansion of low-cost biosimilars improving accessibility and treatment adoption
- Transition toward outpatient cancer care models requiring effective supportive therapies
- Improved access to oncology care in emerging markets
Febrile Neutropenia Market Barriers
- Rising antimicrobial resistance complicating empirical therapy choices and treatment outcomes
- Stringent regulatory requirements and lengthy approval timelines for novel therapies
- Delayed market entry of key supportive care therapies in certain regions like Japan
- Limited late-stage pipeline assets constraining innovation and near-term growth
- Increasing biosimilar penetration driving price pressure and long-term revenue decline for innovator products
- Structural shrinking of short-acting G-CSF market opportunity
- Reimbursement-driven delays in febrile neutropenia access in certain markets
- Gaps in diagnosis and risk stratification capabilities
- Lack of comprehensive epidemiological data in certain geographies
Scope of the Febrile Neutropenia Market Report
- Study Period: 2022-2036
- Coverage: 7MM
- Key Febrile Neutropenia Companies: Evive Biotech , Acrotech Biopharma Inc , APOGEPHA Arzneimittel GmbH , Teva Pharmaceuticals , Assertio , Kyowa Kirin, Inc.- U.S. , Terumo Medical Corporation , BeyondSpring and others.
- Key Febrile Neutropenia Therapies: RYZNEUTA [F-627 (efbemalenograstim alfa)], Lipegfilgrastim (LONQUEX), Filgrastim (GRANIX), Eflapegrastim-xnst (ROLVEDON), Pegfilgrastim (G-LASTA), Plinabulin, and others
- Febrile Neutropenia Therapeutic Assessment: Febrile Neutropenia current marketed and emerging therapies
- Febrile Neutropenia Market Dynamics: Market drivers and market barriers
- Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Porter’s five forces, Market entry strategies
- Febrile Neutropenia Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us
Kanishk
kkumar@delveinsight.com
